<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RILUTEK- riluzole tablet, film coated </strong><br>sanofi-aventis U.S. LLC<br></p></div>
<h1>RILUTEK® <br>(riluzole) Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">RILUTEK® (riluzole) is a member of the benzothiazole class. Chemically, riluzole is 2-amino-6-(trifluoromethoxy)benzothiazole. Its molecular formula is C<span class="Sub">8</span>H<span class="Sub">5</span>F<span class="Sub">3</span>N<span class="Sub">2</span>OS and its molecular weight is 234.2. Its structural formula is as follows:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e49d207d-8e32-4183-94ba-cd264f124090&amp;name=rilutek-01.jpg"></p>
<p>Riluzole is a white to slightly yellow powder that is very soluble in dimethylformamide, dimethylsulfoxide and methanol, freely soluble in dichloromethane, sparingly soluble in 0.1 N HCl and very slightly soluble in water and in 0.1 N NaOH. RILUTEK is available as a capsule-shaped, white, film-coated tablet for oral administration containing 50 mg of riluzole. Each tablet is engraved with "RPR 202" on one side.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>Inactive Ingredients</h2>
<p class="First"><span class="Bold">Core:</span> anhydrous dibasic calcium phosphate, USP; microcrystalline cellulose, NF; anhydrous colloidal silica, NF; magnesium stearate, NF; croscarmellose sodium, NF.</p>
<p><span class="Bold">Film coating:</span> hypromellose, USP; polyethylene glycol 6000; titanium dioxide, USP.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Clinical_Pharmacology"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">The etiology and pathogenesis of <span class="product-label-link" type="condition" conceptid="373182" conceptname="Amyotrophic lateral sclerosis">amyotrophic lateral sclerosis</span> (ALS) are not known, although a number of hypotheses have been advanced. One hypothesis is that motor neurons, made vulnerable through either genetic predisposition or environmental factors, are injured by glutamate. In some cases of familial ALS the enzyme superoxide dismutase has been found to be defective.</p>
<p>The mode of action of RILUTEK is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release, 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors. </p>
<p>Riluzole has also been shown, in a single study, to delay median time to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in a transgenic mouse model of ALS. These mice express human superoxide dismutase bearing one of the mutations found in one of the familial forms of human ALS.</p>
<p>It is also neuroprotective in various <span class="Italics">in vivo</span> experimental models of neuronal injury involving excitotoxic mechanisms. In <span class="Italics">in vitro</span> tests, riluzole protected cultured rat motor neurons from the excitotoxic effects of glutamic acid and prevented the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of cortical neurons induced by <span class="product-label-link" type="condition" conceptid="313601" conceptname="Oxygen supply absent">anoxia</span>.</p>
<p>Due to its blockade of glutamatergic neurotransmission, riluzole also exhibits myorelaxant and sedative properties in animal models at doses of 30 mg/kg (about 20 times the recommended human daily dose) and anticonvulsant properties at a dose of 2.5 mg/kg (about 2 times the recommended human daily dose).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Riluzole is well-absorbed (approximately 90%), with average absolute oral bioavailability of about 60% (CV=30%). Pharmacokinetics are linear over a dose range of 25 to 100 mg given every 12 hours. A high fat meal decreases absorption, reducing AUC by about 20% and peak blood levels by about 45%. The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses. With multiple-dose administration, riluzole accumulates in plasma by about  twofold and steady-state is reached in less than 5 days. Riluzole is 96% bound to plasma proteins, mainly to albumin and lipoproteins over the clinical concentration range.</p>
<p>The 50 mg market tablet was equivalent, with respect to AUC, to the tablet used in the dose ranging clinical trials, while the C<span class="Sub">max</span> was approximately 30% higher. Both tablets have been used in clinical trials. However, if doses greater than those recommended are given, it is likely that higher plasma levels will be achieved, the safety of which has not been established (see <a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>Metabolism and Elimination</h2>
<p class="First">Riluzole is extensively metabolized to six major and a number of minor metabolites, not all of which have been identified. Some metabolites appear pharmacologically active in <span class="Italics">in vitro</span> assays. The metabolism of riluzole is mostly hepatic and consists of cytochrome P450-dependent hydroxylation and glucuronidation.</p>
<p>There is marked interindividual variability in the clearance of riluzole, probably attributable to variability of CYP 1A2 activity, the principal isozyme involved in N-hydroxylation.</p>
<p><span class="Italics">In vitro</span> studies using liver microsomes show that hydroxylation of the primary amine group producing N-hydroxyriluzole is the main metabolic pathway in human, monkey, dog and rabbit. In humans, cytochrome P450 1A2 is the principal isozyme involved in N-hydroxylation. <span class="Italics">In vitro</span> studies predict that CYP 2D6, CYP 2C19, CYP 3A4 and CYP 2E1 are unlikely to contribute significantly to riluzole metabolism in humans. Whereas direct glucuroconjugation of riluzole (involving the glucurotransferase isoform UGT-HP4) is very slow in human liver microsomes, N-hydroxyriluzole is readily conjugated at the hydroxylamine group resulting in the formation of O- (&gt;90%) and N-glucuronides.</p>
<p>Following a single 150 mg dose of <span class="Sup">14</span>C-riluzole to 6 healthy males, 90% and 5% of the radioactivity was recovered in the urine and feces respectively over a period of 7 days. Glucuronides accounted for more than 85% of the metabolites in urine. Only 2% of a riluzole dose was recovered in the urine as unchanged drug. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Special_Populations"></a><a name="section-2.4"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h3>
<p class="First">The area-under-the-curve (AUC) of riluzole, after a single 50 mg oral dose, increases by about 1.7-fold in patients with mild chronic liver insufficiency (n=6; Child-Pugh's score A) and by about 3-fold in patients with moderate chronic liver insufficiency (n=6; Child-Pugh's score B) compared to healthy volunteers (n=12) (see <a href="#Warnings">WARNINGS</a> and <a href="#Precautions">PRECAUTIONS</a>). The pharmacokinetics of riluzole have not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First">There is no significant difference in pharmacokinetic parameters between patients with moderate (n=5; creatinine clearance 30–50 ml.min<span class="Sup">-1</span>) and severe (n=7; creatinine clearance &lt;30 ml.min<span class="Sup">-1</span>) <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and healthy volunteers (n=12) after a single oral dose of 50 mg riluzole. The pharmacokinetics of riluzole have not been studied in patients undergoing hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.3"></a><p></p>
<h3>Age</h3>
<p class="First">The pharmacokinetic parameters of riluzole after multiple dose administration (4.5 days of treatment at 50 mg riluzole b.i.d.) are not affected in the elderly (≥ 70 years).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.4"></a><p></p>
<h3>Gender</h3>
<p class="First">No gender effect on riluzole pharmacokinetics has been found in young or elderly healthy subjects. However, in one placebo-controlled clinical trial with population pharmacokinetics, riluzole mean clearance was found to be 30% lower in female patients (corresponding to an approximate increase in AUC of 45%) as compared to male patients. No  favorable or adverse effects of riluzole in relation to gender were seen in controlled trials, however.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.5"></a><p></p>
<h3>Smoking</h3>
<p class="First">Patients who smoke cigarettes eliminate riluzole 20% faster than non-smoking patients, based on a population pharmacokinetic analysis on data from 128 ALS patients, of whom 19 were smokers. However, there is no need for dosage adjustment in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.6"></a><p></p>
<h3>Race</h3>
<p class="First">A clinical study conducted to evaluate the pharmacokinetics of riluzole and its metabolite following repeated oral administration twice daily in healthy Japanese and Caucasian adult males showed that there were no significant racial differences in pharmacokinetic parameters between the Japanese and Caucasian subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-2.5"></a><p></p>
<h2>Clinical Trials</h2>
<p class="First">The efficacy of RILUTEK as a treatment of ALS was established in two adequate and well-controlled trials in which the time to tracheostomy or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was longer for patients randomized to RILUTEK than for those randomized to placebo.</p>
<p>These studies admitted patients with either familial or sporadic ALS, a disease duration of less than 5 years, and a baseline forced <span class="product-label-link" type="condition" conceptid="4147814" conceptname="Vital capacity">vital capacity</span> greater than or equal to 60%.</p>
<p>In one study, performed in France and Belgium, 155 ALS patients were followed for at least 13 months (maximum duration 18 months) after being randomized to either 100 mg/day (given 50 mg BID) of RILUTEK or placebo.</p>
<p>Figure 1, which follows, displays the survival curves for time to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or tracheostomy. The vertical axis represents the proportion of individuals alive without tracheostomy at various times following treatment initiation (horizontal axis). Although these survival curves were not statistically significantly different when evaluated by the analysis specified in the study protocol (Logrank test p=0.12), the difference was found to be significant by another appropriate analysis (Wilcoxon test p=0.05). As seen, the study showed an early increase in survival in patients given riluzole. Among the patients in whom treatment failed during the study (tracheostomy or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) there was a difference between the treatment groups in median survival of approximately 90 days. There was no statistically significant difference in mortality at the end of the study.</p>
<p><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e49d207d-8e32-4183-94ba-cd264f124090&amp;name=rilutek-02.jpg"></p>
<p>In the second study, performed in both Europe and North America, 959 ALS patients were followed for at least 1 year (North American centers) and up to 18 months (European centers) after being randomized to either 50, 100, 200 mg/day of RILUTEK or placebo. </p>
<p>Figure 2, which follows, displays the survival curves for time to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or tracheostomy for patients randomized to either 100 mg/day of RILUTEK or placebo. Although these survival curves were not statistically significantly different when evaluated by the analysis specified in the study protocol (Logrank test p = 0.076), the difference was found to be significant by another appropriate analysis (Wilcoxon test p = 0.05). Not displayed in Figure 2 are the results of 50 mg/day of RILUTEK which could not be statistically distinguished from placebo and the results of 200 mg/day which are essentially identical to 100 mg/day. As seen, the study showed an early increase in survival in patients given riluzole. Among the patients in whom treatment failed during the study (tracheostomy or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) there was a difference between the treatment groups in median survival of approximately 60 days. There was no statistically significant difference in mortality at the end of the study.</p>
<p><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e49d207d-8e32-4183-94ba-cd264f124090&amp;name=rilutek-03.jpg"></p>
<p>Although riluzole improved early survival in both studies, measures of muscle strength and neurological function did not show a benefit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">RILUTEK is indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="373182" conceptname="Amyotrophic lateral sclerosis">amyotrophic lateral sclerosis</span> (ALS). Riluzole extends survival and/or time to tracheostomy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">RILUTEK is contraindicated in patients who have a history of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to riluzole or any of the tablet components. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span> / Monitoring Liver Chemistries</h2>
<p class="First">RILUTEK should be prescribed with care in patients with current evidence or history of abnormal liver function indicated by significant abnormalities in serum transaminase (ALT/SGPT; AST/<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), bilirubin, and/or gamma-glutamate transferase (GGT) levels (see <a href="#Precautions">PRECAUTIONS</a> and <a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a> sections). Baseline elevations of several LFTs (especially elevated bilirubin) should preclude the use of RILUTEK.</p>
<p>RILUTEK, even in patients without a prior history of liver disease, causes serum aminotransferase elevations. Treatment should be discontinued if ALT levels are ≥ 5 × ULN or if clinical <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> develops.</p>
<p> Experience in almost 800 ALS patients indicates that about 50% of riluzole-treated patients will experience at least one ALT/SGPT level above the upper limit of normal, about 8% will have elevations &gt; 3 × ULN, and about 2% of patients will have elevations &gt; 5 × ULN. A single non-ALS patient with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> treated with concomitant carbamazepine and phenobarbital experienced marked, rapid elevations of liver enzymes with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (ALT 26 × ULN, AST 17 × ULN, and bilirubin 11 × ULN) four months after starting RILUTEK; these returned to normal 7 weeks after treatment discontinuation.</p>
<p>Maximum increases in serum ALT usually occurred within 3 months after the start of riluzole therapy and were usually transient when &lt; 5 times ULN. In trials, if ALT levels were &lt; 5 times ULN, treatment continued and ALT levels usually returned to below 2 times ULN within 2 to 6 months. Treatment in studies was discontinued, however, if ALT levels exceeded 5 × ULN, so that there is no experience with continued treatment of ALS patients once ALT values exceed 5 times ULN. There were rare instances of <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. There is limited experience with rechallenge of patients who have had RILUTEK discontinued for ALT &gt; 5 × ULN, but there is the possibility of increased ALT values reoccurring (see <a href="#Laboratory_Tests">PRECAUTIONS: Laboratory Tests</a>). Therefore, rechallenge is not recommended.</p>
<p>In postmarketing experience, cases of clinical <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> associated with riluzole have been reported, including with fatal outcome.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></h2>
<p class="First">Among approximately 4000 patients given riluzole for ALS, there were three cases of marked <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count less than 500/mm<span class="Sup">3</span>), all seen within the first 2 months of riluzole treatment. In one case, neutrophil counts rose on continued treatment. In a second case, counts rose after therapy was stopped. A third case was more complex, with marked <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> as well as <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and the etiology of both is uncertain. Patients should be warned to report any febrile illness to their physicians. The report of a febrile illness should prompt treating physicians to check white blood cell counts.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WarnILD"></a><a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> (see <a href="#AR">ADVERSE REACTIONS</a>) have been reported in patients treated with riluzole, some of them severe; upon further investigation, many of these cases were <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>. If respiratory symptoms develop such as <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> and/or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, chest radiography should be performed, and in case of findings suggestive of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> (e.g., bilateral diffuse lung opacities), riluzole should be discontinued immediately. In the majority of the reported cases, symptoms resolved after drug discontinuation and symptomatic treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Precautions"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Use in Patients with Concomitant Disease</h2>
<p class="First">RILUTEK should be used with caution in patients with concomitant liver insufficiency (see <a href="#Warnings">WARNINGS</a>, <a href="#Clinical_Pharmacology">CLINICAL PHARMACOLOGY)</a>. In particular, in cases of RILUTEK-induced hepatic injury manifested by elevated liver enzymes, the effect of the hepatic injury on RILUTEK metabolism is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>Special Populations</h2>
<p class="First">Riluzole should be used with caution in elderly patients whose hepatic function may be compromised due to age. Also, female patients may possess a lower metabolic capacity to eliminate riluzole compared to males (see <a href="#Special_Populations">CLINICAL PHARMACOLOGY: Special Populations</a>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.3"></a><p></p>
<h2>Information for the Patient</h2>
<p class="First">Patients should be advised to report any febrile illness to their physicians (see <a href="#<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>">WARNINGS: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></a>).</p>
<p>Patients should be advised to report any <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> or difficulties in breathing to their physicians (see <a href="#WarnILD">WARNINGS: <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span></a>).</p>
<p>Patients and caregivers should be advised that RILUTEK should be taken on a regular basis and at the same time of the day (<span class="Italics">e.g.,</span> in the morning and evening) each day. If a dose is missed, take the next tablet as originally planned (see <a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a>).</p>
<p>Patients should be warned about the potential for <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and advised not to drive or operate machinery until they have gained sufficient experience on RILUTEK to gauge whether or not it affects their mental and/or motor performance adversely.</p>
<p>Whether alcohol increases the risk of serious hepatotoxicity with RILUTEK is unknown; therefore, patients being treated with RILUTEK should be discouraged from drinking excessive amounts of alcohol.</p>
<p>Patients should also be made aware that RILUTEK should be stored at temperatures between 20°–25°C (68°–77°F) and protected from bright light.</p>
<p>RILUTEK must be kept out of the reach of children.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="Laboratory_Tests"></a><a name="section-6.4"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Serum aminotransferases including ALT levels should be measured before and during riluzole therapy. Serum ALT levels should be evaluated every month during the first 3 months of treatment, every 3 months during the remainder of the first year, and periodically thereafter. Serum ALT levels should be evaluated more frequently in patients who develop elevations (see <a href="#Warnings">WARNINGS</a>).</p>
<p>As noted in the <a href="#Warnings">WARNINGS</a> Section, there is no experience with continued treatment of patients once ALT exceeds 5 × ULN. Treatment should be discontinued if ALT levels are ≥ 5 × ULN or if clinical <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> develops. There is limited experience with rechallenge of patients who have had RILUTEK discontinued for ALT &gt; 5 × ULN, but there is the possibility of increased ALT values reoccurring. Therefore, rechallenge is not recommended.</p>
<p>In the two controlled trials in patients with ALS, the frequency with which values for hemoglobin, hematocrit, and erythrocyte counts fell below the lower limit of normal was greater in RILUTEK-treated patients than in placebo-treated patients; however, these changes were mild and transient. The proportions of patients observed with abnormally low values for these parameters showed a dose-response relationship. Only one patient was discontinued from treatment because of severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. The significance of this finding is unknown.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">There have been no clinical studies designed to evaluate the interaction of riluzole with other drugs.</p>
<p>As with all drugs, the potential for interaction by a variety of mechanisms is a possibility.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5.1"></a><p></p>
<h3>Hepatotoxic Drugs</h3>
<p class="First">The clinical trials in ALS excluded patients on concomitant medications which were potentially hepatotoxic, (<span class="Italics">e.g.,</span> allopurinol, methyldopa, sulfasalazine). Accordingly, there is no information about the safety of administering RILUTEK in conjunction with such medications. If the practitioner chooses to prescribe such a combination, caution should be exercised.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5.2"></a><p></p>
<h3>Drugs Highly Bound To Plasma Proteins</h3>
<p class="First">Riluzole is highly bound (96%) to plasma proteins, binding mainly to serum albumin and to lipoproteins. The effect of riluzole (up to 5 mcg/mL) on warfarin (5 mcg/mL) binding did not show any displacement of warfarin. Conversely, riluzole binding was unaffected by the addition of warfarin, digoxin, imipramine and quinine at high therapeutic concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5.3"></a><p></p>
<h3>Effect of Other Drugs On Riluzole Metabolism</h3>
<p class="First"><span class="Italics">In vitro</span> studies using human liver microsomal preparations suggest that CYP 1A2 is the principal isozyme involved in the initial oxidative metabolism of riluzole and, therefore, potential interactions may occur when riluzole is given concurrently with agents that affect CYP 1A2 activity. Potential inhibitors of CYP 1A2 (<span class="Italics">e.g.,</span> caffeine, phenacetin, theophylline, amitriptyline, and quinolones) could decrease the rate of riluzole elimination, while inducers of CYP 1A2 (<span class="Italics">e.g.,</span> cigarette smoke, charcoal-broiled food, rifampicin, and omeprazole) could increase the rate of riluzole elimination.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5.4"></a><p></p>
<h3>Effect of Riluzole On the Metabolism of Other Drugs</h3>
<p class="First">CYP 1A2 is the principal isoenzyme involved in the initial oxidative metabolism of riluzole; potential interactions may occur when riluzole is given concurrently with other agents which are also metabolized primarily by CYP 1A2 (<span class="Italics">e.g.,</span> theophylline, caffeine, and tacrine). Currently, it is not known whether riluzole has any potential for enzyme induction in humans.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-6.6"></a><p></p>
<h2>Drug Laboratory Test Interactions</h2>
<p class="First">None known</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.7"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Riluzole was not carcinogenic in mice or rats when administered for 2 years at daily oral doses up to 20 mg/kg and 10 mg/kg, respectively, which are approximately equivalent to the maximum human dose on a mg/m<span class="Sup">2</span> basis.</p>
<p>The genotoxic potential of riluzole was evaluated in the bacterial mutagenicity (Ames) test, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> mutation assay in L5178Y cells, the <span class="Italics">in vitro</span> chromosomal aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and the <span class="Italics">in vivo</span> rat cytogenetic assay and <span class="Italics">in vivo</span> mouse micronucleus assay in bone marrow. There was no evidence of mutagenic or clastogenic potential in the Ames test, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, or the <span class="Italics">in vivo</span> assays in the mouse and rat. There was an equivocal clastogenic response in the <span class="Italics">in vitro</span> human lymphocyte chromosomal aberration assay, which was not reproduced in a second assay performed at equal or higher concentrations; riluzole was therefore considered non-clastogenic in the human lymphocyte assay.</p>
<p>N-hydroxyriluzole, the major active metabolite of riluzole, caused chromosomal damage in the <span class="Italics">in vitro</span> mammalian mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and in the <span class="Italics">in vitro</span> micronucleus assay that used the same mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell line, L5178Y. N-hydroxyriluzole was not mutagenic in this cell line when tested in the HPRT gene mutation assay, and was negative in the Ames bacterial gene mutation assay (with and without rat or hamster S9), the <span class="Italics">in vitro</span> UDS assay in rat hepatocytes, the chromosomal aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and the <span class="Italics">in vivo</span> mouse bone marrow micronucleus test.</p>
<p>Riluzole impaired fertility when administered to male and female rats prior to and during mating at an oral dose of 15 mg/kg or 1.5 times the maximum daily dose on a mg/m<span class="Sup">2</span> basis (see <a href="#Pregnancy">PRECAUTIONS: "Pregnancy"</a> for effects on fertility). </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Pregnancy"></a><a name="section-6.8"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.8.1"></a><p></p>
<h3>Pregnancy category C</h3>
<p class="First">Oral administration of riluzole to pregnant animals during the period of organogenesis caused embryotoxicity in rats and rabbits at doses of 27 mg/kg and 60 mg/kg, respectively, or 2.6 and 11.5 times, respectively, the recommended maximum human daily dose on a mg/m<span class="Sup">2</span> basis. Evidence of maternal toxicity was also observed at these doses.</p>
<p>When administered to rats prior to and during mating (males and females) and throughout gestation and lactation (females), riluzole produced adverse effects on pregnancy (decreased implantations, increased intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) and offspring viability and growth at an oral dose of 15 mg/kg or 1.5 times the maximum daily dose on a mg/m<span class="Sup">2</span> basis. </p>
<p>There are no adequate and well-controlled studies in pregnant women. Riluzole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.9"></a><p></p>
<h2>Nursing Women</h2>
<p class="First">In rat studies, <span class="Sup">14</span>C-riluzole was detected in maternal milk. It is not known whether riluzole is excreted in human breast milk. Because many drugs are excreted in human milk, and because the potential for serious adverse reactions in nursing infants from RILUTEK® is unknown, women should be advised not to breast-feed during treatment with RILUTEK.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-6.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Age-related compromised renal and hepatic function may cause a decrease in clearance of riluzole (see <a href="#Special_Populations">CLINICAL PHARMACOLOGY: Special Populations</a>). In controlled clinical trials, about 30% of patients were over 65. There were no differences in adverse effects between younger and older patients.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.11"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and the effectiveness of RILUTEK in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most commonly observed AEs associated with the use of RILUTEK more frequently than placebo treated patients were: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, decreased lung function, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4015676" conceptname="Circumoral paresthesia">circumoral paresthesia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="4015676" conceptname="Circumoral paresthesia">circumoral paresthesia</span> were dose related. </p>
<p>Approximately 14% (n = 141) of the 982 individuals with ALS who received RILUTEK in pre-marketing clinical trials discontinued treatment because of an adverse experience. Of those patients who discontinued due to adverse events, the most commonly reported were: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and ALT elevations. In a dose response study in ALS patients, the rates of discontinuation of RILUTEK for <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and ALT elevation were dose related.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>Incidence in Controlled ALS Clinical Studies</h2>
<p class="First">Table 1 lists treatment-emergent signs and symptoms that occurred in at least 2% of patients with ALS treated with RILUTEK (n=794) participating in placebo-controlled trials and were numerically greater in the patients treated with RILUTEK 100 mg/day than with placebo or for which a dose response relationship is suggested.</p>
<p>The prescriber should be aware that these figures cannot be used to predict the frequency of adverse experiences in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical studies. Inspection of these frequencies, however, does provide the prescriber with one basis to estimate the relative contribution of drug and non-drug factors to the AE incidences in the population studied.</p>
<table width="90%">
<caption><span>Table 1 Adverse Events Occurring in Placebo-Controlled Clinical Trials</span></caption>
<col align="left" valign="top" width="36%">
<col align="left" valign="top" width="16%">
<col align="left" valign="top" width="16%">
<col align="left" valign="top" width="16%">
<col align="left" valign="top" width="16%">
<thead><tr class="First Last">
<th align="left" valign="top">Body System /<br>Adverse Event<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th align="left">Riluzole<br>50 mg/day<br>(N=237)</th>
<th align="left">Riluzole<br>100 mg/day<br>(N=313)</th>
<th align="left">Riluzole<br>200 mg/day<br>(N=244)</th>
<th align="left">Placebo<br> <br>(N=320)</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Percentage of patients reporting events</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Bold">Body as a Whole</span></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="left">14.8</td>
<td align="left">19.2</td>
<td align="left">20.1</td>
<td align="left">12.2</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="left">8.0</td>
<td align="left">7.3</td>
<td align="left">7.0</td>
<td align="left">6.6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="left">6.8</td>
<td align="left">5.1</td>
<td align="left">7.8</td>
<td align="left">3.8</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="left">1.7</td>
<td align="left">3.2</td>
<td align="left">4.1</td>
<td align="left">2.5</td>
</tr>
<tr>
<td align="left">Aggravation reaction</td>
<td align="left">0.4</td>
<td align="left">1.3</td>
<td align="left">2.0</td>
<td align="left">0.9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td align="left">0.4</td>
<td align="left">0.6</td>
<td align="left">1.2</td>
<td align="left">0.0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Digestive</span></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="left">12.2</td>
<td align="left">16.3</td>
<td align="left">20.5</td>
<td align="left">10.6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="left">4.2</td>
<td align="left">4.2</td>
<td align="left">4.5</td>
<td align="left">1.6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="left">2.5</td>
<td align="left">3.8</td>
<td align="left">6.1</td>
<td align="left">5.0</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="left">3.8</td>
<td align="left">3.2</td>
<td align="left">8.6</td>
<td align="left">3.8</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left">5.5</td>
<td align="left">2.9</td>
<td align="left">9.0</td>
<td align="left">3.1</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td align="left">2.5</td>
<td align="left">2.6</td>
<td align="left">2.0</td>
<td align="left">1.9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td align="left">0.8</td>
<td align="left">1.0</td>
<td align="left">1.2</td>
<td align="left">0.0</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">Tooth disorder</span></td>
<td align="left">0.0</td>
<td align="left">1.0</td>
<td align="left">1.2</td>
<td align="left">0.3</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral Moniliasis</span></td>
<td align="left">0.4</td>
<td align="left">0.6</td>
<td align="left">1.2</td>
<td align="left">0.3</td>
</tr>
<tr>
<td class="Bold" align="left">Nervous</td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span></td>
<td align="left">5.9</td>
<td align="left">6.1</td>
<td align="left">5.3</td>
<td align="left">5.9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="left">4.2</td>
<td align="left">4.5</td>
<td align="left">6.1</td>
<td align="left">5.0</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="left">5.1</td>
<td align="left">3.8</td>
<td align="left">12.7</td>
<td align="left">2.5</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td align="left">3.0</td>
<td align="left">3.5</td>
<td align="left">2.0</td>
<td align="left">3.4</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="left">2.1</td>
<td align="left">3.5</td>
<td align="left">2.9</td>
<td align="left">3.4</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="left">0.8</td>
<td align="left">1.9</td>
<td align="left">4.1</td>
<td align="left">1.3</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td align="left">2.5</td>
<td align="left">1.9</td>
<td align="left">4.5</td>
<td align="left">0.9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4015676" conceptname="Circumoral paresthesia">Circumoral paresthesia</span></td>
<td align="left">1.3</td>
<td align="left">1.6</td>
<td align="left">3.3</td>
<td align="left">0.0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Skin and Appendages</span></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="left">3.8</td>
<td align="left">3.8</td>
<td align="left">2.5</td>
<td align="left">3.1</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span></td>
<td align="left">0.8</td>
<td align="left">1.6</td>
<td align="left">1.6</td>
<td align="left">0.6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td align="left">0.0</td>
<td align="left">1.0</td>
<td align="left">1.2</td>
<td align="left">0.6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span></td>
<td align="left">0.0</td>
<td align="left">0.6</td>
<td align="left">1.2</td>
<td align="left">0.0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Respiratory</span></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">Decreased lung function</td>
<td align="left">13.1</td>
<td align="left">10.2</td>
<td align="left">16.0</td>
<td align="left">9.4</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="left">8.9</td>
<td align="left">6.4</td>
<td align="left">7.8</td>
<td align="left">6.3</td>
</tr>
<tr>
<td align="left">Increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></td>
<td align="left">2.1</td>
<td align="left">2.6</td>
<td align="left">3.7</td>
<td align="left">1.6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="left">0.4</td>
<td align="left">1.0</td>
<td align="left">1.6</td>
<td align="left">0.9</td>
</tr>
<tr>
<td align="left"><span class="Bold">Cardiovascular</span></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="left">6.8</td>
<td align="left">5.1</td>
<td align="left">3.3</td>
<td align="left">4.1</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td align="left">1.3</td>
<td align="left">2.6</td>
<td align="left">2.0</td>
<td align="left">1.3</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span></td>
<td align="left">0.4</td>
<td align="left">1.0</td>
<td align="left">0.8</td>
<td align="left">0.3</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span></td>
<td align="left">0.4</td>
<td align="left">0.6</td>
<td align="left">1.2</td>
<td align="left">0.9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span></td>
<td align="left">0.8</td>
<td align="left">0.0</td>
<td align="left">1.6</td>
<td align="left">0.6</td>
</tr>
<tr>
<td align="left"><span class="Bold">Metabolic and Nutritional Disorders</span></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span></td>
<td align="left">4.6</td>
<td align="left">4.8</td>
<td align="left">3.7</td>
<td align="left">4.7</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
<td align="left">4.2</td>
<td align="left">2.9</td>
<td align="left">3.3</td>
<td align="left">2.2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Musculoskeletal System</span></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="left">5.1</td>
<td align="left">3.5</td>
<td align="left">1.6</td>
<td align="left">3.4</td>
</tr>
<tr>
<td class="Bold" align="left">Urogenital System</td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td align="left">2.5</td>
<td align="left">2.6</td>
<td align="left">4.5</td>
<td align="left">2.2</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></td>
<td align="left">0.0</td>
<td align="left">1.0</td>
<td align="left">1.2</td>
<td align="left">0.3</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Other Adverse Events Observed</h2>
<p class="First">Other events which occurred in more than 2% of patients treated with RILUTEK 100 mg/day but equally or more frequently in the placebo group included: <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">heart arrest</span>, increased <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, and <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>.</p>
<p>The overall adverse event profile for RILUTEK was similar between females and males, and was independent of age. Because the largest non-white racial subgroup was only 2% of patients exposed to RILUTEK (18/794) in placebo-controlled trials, there are insufficient data to support a statement regarding the distribution of adverse experience reports by race. In ALS studies, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> did occur more commonly in females (11%) than in males (4%). There was not a difference between females and males in the rates of discontinuation of RILUTEK for individual adverse experiences.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Other Adverse Events Observed During All Clinical Trials</h2>
<p class="First">RILUTEK has been administered to 1713 individuals during all clinical trials, some of which were placebo-controlled. During these trials, all adverse events were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse events, similar types of events were grouped into a smaller number of standardized categories using modified COSTART dictionary terminology. The frequencies presented represent the proportion of the 1713 individuals exposed to RILUTEK who experienced an event of the type cited on at least one occasion while receiving RILUTEK. All reported events are included except those already listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug.</p>
<p>Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: <span class="Italics">frequent</span> adverse events are defined as those occurring in at least 1/100 patients; <span class="Italics">infrequent</span> adverse events are those occurring in 1/100 to 1/1000 patients; <span class="Italics">rare</span> adverse events are those occurring in fewer than 1/1000 patients.</p>
<p><span class="Bold">Body as a Whole: </span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">Hostility</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">1</a>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">intentional injury</span>, enlarged abdomen, neoplasm. <span class="Italics">Rare</span>: <span class="product-label-link" type="condition" conceptid="4283669" conceptname="Acrodynia due to mercury">Acrodynia</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</p>
<p><span class="Bold">Digestive System: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, gastrointestinal ulceration, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gum hemorrhage</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, tenesmus, <span class="product-label-link" type="condition" conceptid="4268622" conceptname="Stricture of esophagus">esophageal stenosis</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">Cheilitis</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4291807" conceptname="Biliary colic">biliary pain</span>, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous enterocolitis</span>, enlarged salivary gland, <span class="product-label-link" type="condition" conceptid="4217621" conceptname="Black hairy tongue">tongue discoloration</span>, <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">tooth caries</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
<p><span class="Bold">Nervous System: </span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="438737" conceptname="Acute paranoid reaction">paranoid reaction</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">increased libido</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="4318408" conceptname="Subdural hematoma">subdural hematoma</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">facial paralysis</span>, <span class="product-label-link" type="condition" conceptid="374022" conceptname="Hemiplegia">hemiplegia</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">acute brain syndrome</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, <span class="product-label-link" type="condition" conceptid="375557" conceptname="Cerebral embolism">cerebral embolism</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">psychotic depression</span>, <span class="product-label-link" type="condition" conceptid="444434" conceptname="Schizophreniform disorder">schizophrenic reaction</span>, <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span>, wristdrop.</p>
<p><span class="Bold">Skin and Appendages: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">Skin ulceration</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">fungal dermatitis</span><a href="#footnote-2" class="Sup">1</a>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span><a href="#footnote-2" class="Sup">1</a>, skin <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4266083" conceptname="Granuloma faciale">skin granuloma</span>, <span class="product-label-link" type="condition" conceptid="4042856" conceptname="Fibrous nodule">skin nodule</span>.</p>
<p><span class="Bold">Respiratory System: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccup</span>, <span class="product-label-link" type="condition" conceptid="4338843" conceptname="Disorder of pleura">pleural disorder</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawn</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">lung edema</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span><a href="#footnote-2" class="Sup">1</a>, lung carcinoma, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="260041" conceptname="Candidiasis of lung">respiratory moniliasis</span>, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>.</p>
<p><span class="Bold">Cardiovascular System: </span><span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, lower extremity <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolus</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span><a href="#footnote-2" class="Sup">1</a>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, mesenteric artery occlusion, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>.</p>
<p><span class="Bold">Metabolic and Nutritional Disorders: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4048509" conceptname="Respiratory acidosis">respiratory acidosis</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span><a href="#footnote-2" class="Sup">1</a>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">Generalized edema</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesteremia</span>.</p>
<p><span class="Bold">Endocrine System: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid neoplasia</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes insipidus</span>, <span class="product-label-link" type="condition" conceptid="138713" conceptname="Disorder of parathyroid gland">parathyroid disorder</span>.</p>
<p><span class="Bold">Hemic and Lymphatic System: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">hypochromic anemia</span>, <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.</p>
<p><span class="Bold">Musculoskeletal System: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthrosis</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span><a href="#footnote-2" class="Sup">1</a>, bone neoplasm. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Bone necrosis</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>.</p>
<p><span class="Bold">Special Senses: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span>, <span class="product-label-link" type="condition" conceptid="438738" conceptname="Panophthalmitis">ophthalmitis</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">Blepharitis</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="378163" conceptname="Hyperacusis">hyperacusis</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">vestibular disorder</span>.</p>
<p><span class="Bold">Urogenital System: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">Urinary urgency</span>, <span class="product-label-link" type="condition" conceptid="4298419" conceptname="Cloudy urine">urine abnormality</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney calculus</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, prostate carcinoma, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">kidney pain</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>. <span class="Italics">Rare</span>: <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4153106" conceptname="Abscess of breast">breast abscess</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span>, enlarged <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">uterine fibroids</span>, <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal moniliasis</span>.</p>
<p><span class="Bold">Laboratory Tests: </span><span class="Italics">Infrequent:</span> Increased gamma glutamyl transferase<span class="Italics">,</span> abnormal liver function/tests, increased alkaline phosphatase, positive direct Coombs test, increased gamma globulins. <span class="Italics">Rare:</span> increased lactic dehydrogenase.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">1</a></dt>
<dd>= <span class="Bold">AE frequency ≤  to placebo</span>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No specific antidote or information on treatment of overdosage with RILUTEK is available. In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, RILUTEK therapy should be discontinued immediately. Experience with riluzole <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in humans is limited.  Neurological and <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>, acute <span class="product-label-link" type="condition" conceptid="373764" conceptname="Toxic encephalopathy">toxic encephalopathy</span> with <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> have been observed in isolated cases. Treatment should be supportive and directed toward alleviating symptoms.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> may be rapidly reversible after treatment with methylene blue.</p>
<p>The estimated oral median lethal dose is 94 mg/kg and 39 mg/kg for male mice and rats, respectively.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Dosage_And_Administration"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose for RILUTEK is 50 mg every 12 hours. No increased benefit can be expected from higher daily doses, but adverse events are increased. </p>
<p>RILUTEK tablets should be taken at least an hour before, or two hours after, a meal to avoid a food-related decrease in bioavailability.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.1"></a><p></p>
<h3>Patients with Impaired Hepatic Function</h3>
<p class="First">see <a href="#Warnings">WARNINGS</a>, <a href="#Precautions">PRECAUTIONS</a>, <a href="#Clinical_Pharmacology">CLINICAL PHARMACOLOGY</a>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">RILUTEK 50 mg tablets are white, film-coated, capsule-shaped and engraved with "RPR 202" on one side. RILUTEK is supplied in bottles of 60 tablets, NDC 0075-7700-60.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">STORE AT CONTROLLED ROOM TEMPERATURE 20°–25°C (68°–77°F) AND PROTECT FROM BRIGHT LIGHT.</span></p>
<p><span class="Bold">KEEP OUT OF THE REACH OF CHILDREN.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1></h1>
<p class="First">Revised November 2012</p>
<p>Manufactured for:<br>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807<br>A SANOFI COMPANY</p>
<p>© 2012 sanofi-aventis U.S. LLC</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 mg - 60 Tablet Bottle</h1>
<p class="First">NDC 0075-7700-60</p>
<p><span class="Sub">™</span><span class="Bold Italics">RILUTEK</span><span class="Bold"><span class="Sup">®</span></span></p>
<p><span class="Italics">riluzole</span></p>
<p><span class="Bold">Tablets</span></p>
<p><span class="Bold">50</span> mg</p>
<p><span class="Bold">60</span> Tablets</p>
<p><span class="Bold">sanofi aventis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e49d207d-8e32-4183-94ba-cd264f124090&amp;name=rilutek-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RILUTEK 		
					</strong><br><span class="contentTableReg">riluzole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-7700</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>riluzole</strong> (riluzole) </td>
<td class="formItem">riluzole</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>calcium phosphate, dibasic, anhydrous</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RPR;202</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-7700-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020599</td>
<td class="formItem">12/12/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>sanofi-aventis U.S. LLC
							(824676584)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Winthrop Industries</td>
<td class="formItem"></td>
<td class="formItem">297676475</td>
<td class="formItem">MANUFACTURE(0075-7700)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3d0700b2-3cee-4276-8228-dbf608fb2612</div>
<div>Set id: e49d207d-8e32-4183-94ba-cd264f124090</div>
<div>Version: 7</div>
<div>Effective Time: 20121120</div>
</div>
</div> <div class="DistributorName">sanofi-aventis U.S. LLC</div></p>
</body></html>
